Full history for every metric is available with a Kvantra account
Key financial summary
Financials in NOKTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | NOK m | 1.7 | 0.3 | 16.7 | 13.1 | 3.0 | 0.1 | - |
| Operating profit | NOK m | -130 | - | |||||
| Net profit | NOK m | -3 | -16 | -17 | -35 | -72 | -120 | - |
| EPS reported | NOK | -2.37 | - | |||||
| Operating cashflow per share | NOK | -2.22 | - | |||||
| Capex per share | NOK | 0.13 | - | |||||
| FCF per share | NOK | -2.35 | - | |||||
| Free cash flow | NOK m | -118 | - | |||||
| Net debt | NOK m | 52.9 | - | |||||
| Book value equity | NOK m | -27.2 | - | |||||
| Book value per share | NOK | -0.54 | - | |||||
| Number of shares | m | 50.42 | - | |||||
| DPS (TTM paid) | NOK | 0.00 | - |
Financial summary
Financials in NOKTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.73 | - | |||||
| P/S LTM | x | 178.36 | - | |||||
| P/FCF LTM | x | -0.17 | - | |||||
| EV/EBITDA LTM | x | -0.91 | - | |||||
| EV/Sales LTM | x | 991.75 | - | |||||
| Earnings Yield LTM | % | -598.33% | - | |||||
| FCF Yield | % | -592.54% | - | |||||
| Quality | ||||||||
| ROE | % | 439.08% | - | |||||
| ROIC | % | -186.36% | - | |||||
| Operating margin | % | -116046.4% | - | |||||
| Gross margin | % | 100.00% | - | |||||
| FCF/Sales | % | -105687.5% | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -96.30% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | - | |||||
| Dividend Growth | % | 0.00% | - | |||||
| Payout Ratio | % | 0.00% | - | |||||
| FCF/Debt | x | -1.22 | - | |||||
| Net Debt/EBITDA | x | -0.75 | - | |||||
| EBIT/Net interest | x | -34.87 | - | |||||
| Net debt/market cap | % | 264.59% | - | |||||
| Net debt/Equity | x | -1.94 | - | |||||
| Gross debt/equity | x | -3.55 | - | |||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in Norway, Lifecare AS is dedicated to the research and advancement of medical sensor technology for health tracking. A key innovation is Sencell, a compact sensor designed specifically for continuously monitoring glucose levels in diabetic patients. The company, which has its corporate headquarters in Bergen, Norway, commenced operations in 2006.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Norway, Lifecare AS is dedicated to the research and advancement of medical sensor technology for health tracking. A key innovation is Sencell, a compact sensor designed specifically for continuously monitoring glucose levels in diabetic patients. The company, which has its corporate headquarters in Bergen, Norway, commenced operations in 2006.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free